Louis G. Lange is an academician, company founder, professor and investor who serves as Vice President of the Board of Directors at DiNAQOR.
Dr. Lange has more than 20 years experience in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital. He was among the first academicians in molecular cardiology.
He founded CV Therapeutics, a developer of novel small molecule therapeutics for the treatment of cardiovascular diseases. As the company’s Chairman, CEO and Chief Scientific Officer, Dr. Lange led its 1996 IPO and the overall pipeline development and regulatory approval for Ranexa®, a first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years in the US. He also led the approval of Lexiscan®, a first-in-class adenosine A2a receptor agonist for use in myocardial perfusion imaging studies. Dr. Lange oversaw the sale of CV Therapeutics to Gilead Sciences in 2009 for $1.4 billion dollars.
He served as a Senior Advisor with Gilead Sciences, and is a partner at leading digital health investment firm Asset Management Ventures.
Dr. Lange obtained a Bachelor’s degree from the University of Rochester, an MD from Harvard University and a PhD in Biological Chemistry, also from Harvard University.